P. Boriack-Sjodin

发表

Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2003 .

Mapping Sonic Hedgehog-Receptor Interactions by Steric Interference*

K. Williams, E. Day, P. Boriack-Sjodin, 2000, The Journal of Biological Chemistry.

Structural analysis of inhibitor binding to human carbonic anhydrase II

Samantha G. Zeitlin, D. Christianson, P. Boriack-Sjodin, 1998, Protein science : a publication of the Protein Society.

RNA-modifying proteins as anticancer drug targets

R. Copeland, P. Boriack-Sjodin, S. Ribich, 2018, Nature Reviews Drug Discovery.

An antibody loop replacement design feasibility study and a loop-swapped dimer structure.

L. A. Clark, H. V. van Vlijmen, J. Eldredge, 2008, Protein engineering, design & selection : PEDS.

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

Ning Gao, Haihong Ni, Oluyinka Green, 2011, Antimicrobial Agents and Chemotherapy.

Epigenetic Proteins as Emerging Drug Targets

P. Boriack-Sjodin, 2020 .

Structure-based Mutagenesis Reveals Distinct Functions for Ras Switch 1 and Switch 2 in Sos-catalyzed Guanine Nucleotide Exchange*

J Kuriyan, D. Bar-Sagi, J. Kuriyan, 2001, The Journal of Biological Chemistry.

Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations.

P. Boriack-Sjodin, Kerry E. Murphy-Benenato, Ning Gao, 2014, Bioorganic & medicinal chemistry letters.

A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity

M. Scholle, R. Copeland, J. Hirsch, 2020, SLAS discovery : advancing life sciences R & D.

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.

Tim J. Wigle, K. Swinger, T. Riera, 2015, ACS medicinal chemistry letters.

Pyrazolone based TGFbetaR1 kinase inhibitors.

C. Chuaqui, K. Guckian, P. Boriack-Sjodin, 2010, Bioorganic & medicinal chemistry letters.

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Tim J. Wigle, T. Riera, R. Copeland, 2016, ACS medicinal chemistry letters.

CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism.

Jodi Gureasko, T. Riera, R. Copeland, 2016, Biochemistry.

Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: implications for catalytic proton transfer and inhibitor design.

D. Silverman, P. Laipis, D. Christianson, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

S. Kazmirski, Nancy Su, D. Ogg, 2015, ACS medicinal chemistry letters.

Structure determination of murine mitochondrial carbonic anhydrase V at 2 . 45A resolution : Implications for catalytic proton transfer and inhibitor design ( protein crystallography / enzymology / zinc enzyme / carbon dioxide hydration )

D. Christianson, P. Boriack-Sjodin, Robert W. HECKt, 2005 .

Structure-activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors.

H. V. van Vlijmen, K. Guckian, D. Chin, 2008, Bioorganic & medicinal chemistry letters.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Robert A Copeland, Nigel J Waters, E. Olhava, 2013, Blood.

An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode.

N. Larsen, P. Boriack-Sjodin, M. Morningstar, 2012, The Biochemical journal.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Robert A Copeland, Nigel J Waters, Lei Jin, 2015, Nature chemical biology.

2-Aminoimidazoles inhibitors of TGF-beta receptor 1.

C. Chuaqui, P. Boriack-Sjodin, L. Ling, 2009, Bioorganic & medicinal chemistry letters.

The Elements of Translational Chemical Biology.

Robert A Copeland, R. Copeland, P. Boriack-Sjodin, 2017, Cell chemical biology.

The structural basis of the activation of Ras by Sos

John Kuriyan, D. Bar-Sagi, J. Kuriyan, 1998, Nature.

A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening

K. Swinger, M. Scholle, R. Copeland, 2015, Journal of biomolecular screening.

Protein Methyltransferases: A Distinct, Diverse, and Dynamic Family of Enzymes.

K. Swinger, P. Boriack-Sjodin, 2016, Biochemistry.

The Use of Virtual Screening in ALK5 Kinase Inhibitor Discovery and Validation of Orally Active ALK5 Kinase Inhibitors in Oncology

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008 .

Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: Molecular basis of isozyme‐drug discrimination

D. Silverman, P. Laipis, D. Christianson, 1998, Protein science : a publication of the Protein Society.

Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody.

H. V. van Vlijmen, T. Cachero, Fang Qian, 2006, Protein engineering, design & selection : PEDS.

SM16, an Orally Active TGF-&bgr; Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

C. Chuaqui, Juswinder Singh, Miki N. Newman, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Jodi Gureasko, W. Janzen, T. Riera, 2018, PloS one.

Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design

Woody Sherman, Kenneth Simon, L. A. Clark, 2006, Protein science : a publication of the Protein Society.

Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.

Vijay T. Ahuja, D. Ogg, P. Boriack-Sjodin, 2014, Bioorganic & medicinal chemistry letters.

Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.

Vijay T. Ahuja, D. Ogg, J. Tucker, 2013, Journal of medicinal chemistry.

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.

Herman W T van Vlijmen, Alexey Lugovskoy, Ling Ling Chen, 2014, Methods.

Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.

G. Basarab, A. Eakin, P. Boriack-Sjodin, 2013, Journal of medicinal chemistry.

Negishi cross-coupling enabled synthesis of novel NAD(+)-dependent DNA ligase inhibitors and SAR development.

Matthew D. Miller, M. Gowravaram, C. Eyermann, 2015, Bioorganic & medicinal chemistry letters.

From fragments to leads: novel bacterial NAD+-dependent DNA ligase inhibitors

Matthew D. Miller, C. Eyermann, L. Otterbein, 2015 .

Enzyme–Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality

R. Copeland, P. Boriack-Sjodin, S. Buker, 2019, SLAS discovery : advancing life sciences R & D.

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound.

Diane Joseph-McCarthy, Sameer Kawatkar, D. Joseph-McCarthy, 2012, ACS chemical biology.

Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.

P. Boriack-Sjodin, K. Hull, J. Manchester, 2012, Bioorganic & medicinal chemistry letters.

Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).

T. Keating, P. Boriack-Sjodin, Gabriel Martínez-Botella, 2013, Bioorganic & medicinal chemistry letters.

Identification of a peptide inhibitor for the histone methyltransferase WHSC1

K. Swinger, M. Morrison, W. Janzen, 2018, PloS one.

Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates.

Lei Jin, R. Copeland, P. Boriack-Sjodin, 2016, ACS chemical biology.

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Robert A Copeland, Nigel J Waters, Lei Jin, 2016, ACS medicinal chemistry letters.

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Scott Bowes, Serene Josiah, Juswinder Singh, 2003, Bioorganic & medicinal chemistry letters.

Structure-based design of an intramolecular proton transfer site in murine carbonic anhydrase V.

D. Silverman, P. Laipis, D. Christianson, 1996, Biochemistry.

Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor

Robert A Copeland, Nigel J Waters, E. Olhava, 2014, Biopharmaceutics & drug disposition.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

E. Olhava, Lei Jin, R. Copeland, 2013, Blood.

Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.

Jodi Gureasko, T. Riera, R. Copeland, 2016, Biochemistry.